key: cord-0863268-ghtwxxx0 authors: Xie, Jiang; Covassin, Naima; Fan, Zhengyang; Singh, Prachi; Gao, Wei; Li, Guangxi; Kara, Tomas; Somers, Virend K. title: Association Between Hypoxemia and Mortality in Patients With COVID-19 date: 2020-04-11 journal: Mayo Clin Proc DOI: 10.1016/j.mayocp.2020.04.006 sha: 5f55a576b851f033f2ea5ac413d3b3d64369ffb1 doc_id: 863268 cord_uid: ghtwxxx0 Abstract Objective To identify markers associated with in-hospital death in patients with Coronavirus Disease 2019 (COVID-19) associated pneumonia. Patients and Methods Retrospective, cohort study of 140 patients with moderate-to-critical COVID-19 associated pneumonia requiring oxygen supplementation admitted from January 28th, 2020 to February 28th, 2020, and followed up through March, 13th 2020 in Union Hospital, Wuhan, China. Oxygen saturation (SpO2) and other measures were tested as predictors of in-hospital mortality in survival analysis. Results Of 140 patients with COVID-19 associated pneumonia, 51.4% were men, with a median age of 60 years. Patients with SpO2 ≤90% were older, more likely to be men, to have hypertension and to present with dyspnea than those with SpO2 >90%. Overall, 36 (25.7%) patients died during hospitalization after a median 14-day follow-up. Higher post-oxygen supplementation SpO2 levels were associated with reduced mortality independently of age and sex (hazard ratio per 1-unit SpO2 0.93, 95% confidence interval, 0.91-0.95, P < .001). SpO2 cutoff of 90.5% yielded 84.6% sensitivity and 97.2% specificity for prediction of survival. Dyspnea was also independently associated with death in multivariable analysis (hazard ratio 2.60; 95% confidence interval 1.24-5.43, P = .01). Conclusions In this cohort of COVID-19 patients, hypoxemia was independently associated with in-hospital mortality. These results may help guide clinical management of severe COVID-19 patients, particularly in settings requiring strategic allocation of limited critical care resources. The Coronavirus Disease 2019 (COVID-19) outbreak is now pandemic, straining medical infrastructure, personnel and resources in much of Europe, the Middle East and North America, with significant consequences for clinical management, including rationing of care. 1, 2 Contemporary statistics indicate that 14% of COVID-19 associated pneumonia cases are severe, and 5% of infected patients require intensive care. 3 Mortality rates in severe and critically ill patients are staggering, with the disease being fatal in approximately two-thirds. [4] [5] [6] Given the limited availability of critical care resources, it is imperative to identify simple but reliable predictors of survival in COVID-19 patients who present with at least moderate disease severity. We thus sought to identify and compare differential predictive values of demographic, clinical and laboratory measures in moderate-to-critically ill COVID-19 patients from Wuhan, China. Since COVID-19 primarily attacks the respiratory system, measures that reflect respiratory function would more likely relate to outcomes, particularly in a rapidly progressive disease condition. We therefore focused particularly on dyspnea and systemic oxygenation as potential prognostic biomarkers. This single-center, retrospective cohort study (ChiCTR2000030852) enrolled patients with moderate-to-critical COVID-19 associated pneumonia hospitalized and treated by the Beijing Medical Team in Union Hospital, Wuhan, from January 28 th , 2020 to February 28 th , 2020, with follow-up through March, 13 th 2020. The Beijing Medical Team consisted of physician volunteers from Beijing (Drs Xie and Gao). The Beijing Anzhen Hospital Institutional Review Board approved this study. National Health Committee of the People's Republic of China recommendations for diagnosis of COVID-19 associated pneumonia were used. 7 Patients included in this study met the following criteria: confirmed COVID-19 infection based on real-time reverse transcriptase polymerase chain reaction (RT-PCR) testing from throat swab sample; objective evidence of new-onset pneumonia from chest computed tomography (CT) scan; typical symptoms of pneumonia, i.e., fever, cough, dyspnea, etc.; pneumonia severity graded as moderate, severe or critical. Disease severity was defined according to the classification proposed in the Chinese guidelines for COVID-19 associated pneumonia mentioned above (Supplemental Table) . Moderate cases presented with typical symptoms of pneumonia, i.e. fever, cough, expectoration, dyspnea, with definitive lesions confirmed by CT scan. Severe cases met ≥1 of the following criteria: respiratory rate ≥30bpm, oxygen saturation (SpO 2 ) ≤93% at rest or pressure of arterial oxygen to fractional inspired oxygen concentration ≤300mmHg, >50% progression of lesion as evident from CT scan over the past 48 hours. Lastly, COVID-19 associated pneumonia cases were regarded as critical if they satisfied ≥1 of the following: intubation needed due to respiratory failure, shock, and multiple organ dysfunction requiring intensive care unit treatment. Patients with a very high clinical suspicion of COVID-19 associated pneumonia, namely definite epidemiological exposure (such as family breakout) and other aforementioned features were clinically diagnosed by a specialist team, hospitalized in the same quarantine zone, and were included in this study, despite absence of documented confirmation from nucleic acid screening. Importantly, with regard to the appropriate recent concerns of inclusion of the same patients in different reports , 8 we are aware of only one prior study of patients from Union Hospital which may have included approximately 20 of the 140 patients in our current study. 9 In any event, this paper makes no mention of the key findings in our study, namely the role of dyspnea and hypoxemia as predictors of mortality. All patients were treated following the Chinese guidelines. 7 Although antibiotics were not recommended as routine treatment, they were still considered if patients were found to have evidence of definite or suspected bacterial infection, such as abundant purulent sputum, based on clinical assessment by the responsible physician. Depending on disease severity and clinical assessment of patients at hospitalization, oxygen supplementation by nasal cannula was administered to all patients directly at admission. The oxygen flow ranged from low (1-2 L/min) to high flow (10 L/min) and varied as per patient's response, with the goal of maintaining peripheral oxygen saturation (SpO 2 ) ≥95%. Post-oxygen supplementation SpO 2 was measured from finger oximetry at 2-5 minutes after beginning of oxygen support. If SpO 2 fell below 95%, high flow oxygen supplementation by mask, high nasal flow and mechanical ventilation were considered as needed. Demographic and clinical characteristics were collected from patients or patient's relatives, physical examination, and medical records. Blood measures of white blood cell (WBC) count, neutrophils, lymphocytes, platelets, C-reactive protein (CRP), and D-dimer were acquired. Dates of death were obtained from registration and verified by reviewing the medical record. Followup duration was computed as time interval (in days) from the date of admission to the date of death or the date of discharge, whichever occurred first. Stable patients who remained hospitalized at the end of the follow-up period were regarded to be alive. Continuous data are reported as median and interquartile range (IQR), and categorical data are expressed as frequency and percentage. Wilcoxon signed rank-tests and Pearson's chi-squared tests were used to compare continuous and categorical data between patients with post-oxygen supplementation SpO 2 >90 % vs SpO 2 ≤90%, respectively. Survival was calculated by the Kaplan-Meier method and log-rank test, using as exposures SpO 2 , dyspnea and other demographic and clinical characteristics. Univariate and multivariable (age-and sex-adjusted) Cox proportional hazards models were run, with associations expressed as hazard ratios (HR) and 95% confidence interval (CI). We used a receiver-operating characteristics (ROC) analysis to determine the optimal cut-off of post-oxygen supplementation SpO 2 for predicting survival based on threshold yielding the best combination of sensitivity and specificity. Statistical analysis was performed using JMP, version 14.1 (SAS Institute, Cary, NC), and a two-sided P < .05 was considered significant. Generally, 140 patients were considered to have a very high likelihood of COVID-19 associated and to be classified as critical upon admission (45.10% vs 1.12%, P < .001). With regard to treatment, antibiotics (88.2% vs 67.4%, P = .006) and high nasal flow (9.80% vs 1.12%, P = .02) were more commonly administered in patients with SpO 2 ≤90%. Mechanical ventilation was administered only to these patients group. Analysis of laboratory biomarkers showed that WBC count, neutrophils, CRP, and D-dimer were higher while lymphocytes and platelets were lower in patients with SpO 2 ≤90% vs those with SpO 2 >90%. Age >60 years (HR 12.21, 95% CI 3.74-39.84, P < .001), male sex (HR 2.30, 95% CI 1.13-4.68, P = .02), hypertension (HR 1.97, 95% CI 1.02-3.81, P = .04), and presence of any comorbidity (defined as at least one comorbidity among those shown in Table 1 ) (HR 5.26, 95% CI 2.19-12.64, P < .001) were associated with mortality in univariate analysis (Figure 1 A-D and Table 2 ). Presence of any comorbidity remained a significant risk factor associated with death after adjusting for age and sex (HR 2.65, 95% CI 1.07-6.55, P = .04). Those reporting dyspnea as initial symptom were more likely to die than those who did not report it (Figure 2A ) (38% vs 14%, log-rank P =0.002; HR, 2.94; 95% CI 1.42-6.11, P = .004; Table 2 ). Thirty-five (68.63%) patients with post-oxygen supplementation SpO 2 ≤90% did not survive, while 88 (98.9%) of those >90% did (log-rank P < .001; Figure 2B ). Modeling SpO 2 as a continuous variable in Cox model, we found that for each 1-unit increase in SpO 2 , mortality risk decreased by approximately 8% (HR 0.92, 95% CI 0.91-0.94, P < .001). Dyspnea and SpO 2 were significantly associated with outcomes in multivariable models (HR 2.60; 95% CI 1.24-5.43, P = .01 and HR, 0.93; 95% 0.91-0.95, P < .001, respectively; Table 2 ). Notably, sensitivity analysis restricted to patients with confirmed COVID-19 infection based on RT-PCR testing (n=113) showed that the independent association between dyspnea and death persisted in this sample (HR 3.20; 95% CI 1.26-9.79, P = .014), and no patients with SpO 2 >90% died. SpO 2 ≤ 90% was also strongly associated with death, independently of age and sex (multivariable HR 47.41; 95% CI 6.29-357.48, P < .001). ROC analysis showed that SpO 2 of 90.5% was the optimal SaO 2 cutoff point for predicting survival, demonstrating 84.6% sensitivity, 97.2% specificity and 87.9% accuracy. The overall area under the curve [AUC] was 96% (Figure 3) . In a subgroup analysis of patients ≥80 years (n=13), 9 patients (69.2%) died. All 80 year old patients with SpO 2 >90% (n = 3) on supplemental oxygen survived. Laboratory biomarkers were proved to be associated with mortality by Kaplan-Meier method (Figure 4 A-D) and univariate Cox regression analysis ( These data provide insights into risk factors for mortality in a relatively large sample of moderately to critically ill patients with COVID-19 associated pneumonia. In line with prior reports, 5, 10 our data confirm that age, sex, comorbidities, and inflammatory biomarkers are associated with mortality. We further demonstrate novel and clinically important findings of independent death-associated value of two very simple yet readily assessed characteristics, namely dyspnea and hypoxemia (SpO 2 ≤90% despite oxygen supplementation). We found that dyspnea, an easily assessed symptom, is associated with death in patients with COVID-19 associated pneumonia independently of age and sex. However, a related and also easily acquired clinical measure, oxygen saturation ≤ 90% despite oxygen supplementation, provides a more robust risk factor for fatal outcomes -indeed this measure is the most powerful predictor of the multiple measures we obtained, including the more standard demographic and inflammatory measures reported in earlier studies. 5, 10 Our findings of important prognostic value of dyspnea and hypoxemia for hospitalized patients with COVID-19 associated pneumonia provide a rationale for applying standard scoring strategies to estimate risk and guide treatment even in this patient population, i.e., Scale, the Pneumonia Severity Index, and Acute Physiology and Chronic Health Evaluation II. 11 Future studies assessing the prognostic significance of such models in COVID-19 associated pneumonia are needed. It is important to note that exploratory subgroup analysis on patients 80 years and older, in whom mortality is known to be especially high (69.2% in our study), revealed that all of patients with oxygen saturation above 90% (n = 3) survived. Although these results must be interpreted with caution given the small sample size and possible confounding effects of age, they may be especially relevant considering the limited access to care in areas overwhelmed by COVID-19 cases, with older age possibly being used as a triage criterion for care prioritization. 2 As severe hypoxemia was associated with pronounced elevation of inflammatory markers (higher WBC counts, neutrophil counts, D-dimer, and CRP), acute inflammation of the respiratory system, caused by respiratory virus and/or secondary bacterial infection, 12 may be mechanistically responsible for the significant pulmonary injury and thus persistent hypoxemia. Whether attenuating this inflammatory response early in the disease would improve oxygenation and possibly survival remains to be determined. We acknowledge our study has limitations. A small minority of patients (<6%) had negative RT-PCR testing for infection despite a high clinical probability of COVID-19 associated pneumonia based on clinical and radiographic assessment and epidemiologic exposure. As the proportion of unconfirmed cases is consistent with reported sensitivity data of RT-PCR testing for COVID-19, 13 we presume these were false negatives. Robustness of our findings is further supported by results of a sensitivity analysis showing that dyspnea and SpO 2 ≤90% remained independently associated with mortality in the sample including only patients with confirmed COVID-19 from RT-PCR testing. Second, these data were acquired under emergency situations operating under crisis conditions, as with many other contemporaneous studies from Wuhan. Therefore completeness of data recording, particularly at time of admission, was less than optimal. For example while oxygen supplementation at admission was administered with the goal of achieving SpO 2 ≥95%, the specific amount of oxygen supplementation administered to each patient upon admission was not recorded. Therefore we cannot incorporate comparisons of administered inspired oxygen concentration into our analyses. Similarly, while recognizing that dyspnea has the inherent limitation of subjectivity, no consistent data relative to dyspnea severity, time to intubation/high flow O 2 and time on mechanical ventilation, and changes in SpO 2 during hospitalization were available. The impact of these variables on outcomes in COVID-19 patients warrants further investigation. We report that in moderate-to-critically ill patients with COVID-19, oxygen saturation above 90% with oxygen supplementation indicates a very high likelihood of survival. These patients should thus receive maximal supportive care during the acute illness. We further speculate that patients with oxygen saturation <90% despite oxygen supplementation, in whom there is a particularly high mortality risk, may be more likely to benefit from experimental therapies such as investigational drugs and antibody therapy. Data are presented as median (range) and n (%). The following variables had missing data: WBC (n=136), neutrophil count (n=128) lymphocyte count (n=135), platelets count (n=127), CRP (n=105), and D-dimer (n=83). a Presence of any comorbidity was defined as presence of one or more of the following chronic diseases: hypertension, diabetes, cardiovascular disease, chronic obstructive pulmonary diseases, asthma and endstage renal failure. Abbreviation: COPD = chronic obstructive pulmonary diseases; COVID-19 = coronavirus disease 2019; CRP = C-reactive protein; SpO 2 = oxygen saturation; WBC = white blood cell. Abbreviations: CI = confidence interval; COVID-19 = coronavirus disease 2019; CRP = C-reactive protein; HR = hazard ratio; SpO 2 = oxygen saturation; WBC = white blood cell count. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response A framework for rationing ventilators and critical care beds during the COVID-19 pandemic Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study National Health Committee of the People's Republic of China Editorial concern-possible reporting of the same patients with COVID-19 in different reports Gender differences in patients with COVID-19: focus on severity and mortality Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis Inflammation induced by influenza virus impairs human innate immune control of pneumococcus Detection of 2019 novel coronavirus (2019-nCoV) by realtime RT-PCR We thank all the patients involved in this study.Nothing to disclose. None. SUPPORT STATEMENT: